
    
      Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and
      doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at
      the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles,
      if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15,
      every 28 days, will be administered alone. Treatment will continue unless disease progression
      or intolerable toxicity emerges (see section 5 for detailed treatment plan and dose
      modifications).
    
  